Concepedia
Statistics
Publications
32
Citations
4.3K
H-Index
29
Active since
1969
Affiliations
Pfizer (United States)(Current)
University of North Carolina at Chapel Hill
Harvard University
Emory University
David W. Schulz is an author at Pfizer (United States) specializing in pharmacology, neuropharmacology, and neuroscience.
Publications per year
1969–2008
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino et al. · Journal of Medicinal Chemistry · 2005 · 933 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +17
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Hans Rollema, Leslie K. Chambers, J.W. Coe et al. · Neuropharmacology · 2006 · 535 citations
Public Health, Pharmacology, Pharmacotherapy +14
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.
David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse et al. · Proceedings of the National Academy of Sciences · 1996 · 379 citations
Medicine, Neuroscience, Pharmacology +17
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Thomas Seeger, P A Seymour, Anne W. Schmidt et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 322 citations
Medicine, Pharmacology, Pharmacotherapy +15
Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions
David W. Schulz, Robert L. Macdonald · Brain Research · 1981 · 203 citations
1–5 of 32